Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market is projected to grow at a modest CAGR of 3.5% during the forecast period (2020-2026). The key aspects that drive the growth of the market include the increased cases of diabetes type 2 among the people, the presence of the key players operating in the market providing a wide variety of products, and a large pool of diabetic patients in the emerging economies of the region. Dipeptidyl peptidase 4 (DPP-4) inhibitors release insulin secretion in the body and regulate the sugar levels in the body. However, there are numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors which is likely to challenge the growth of the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market over the forecast period.

Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type. Based on the drug type, the market is segmented as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others. Amongst these drug types of the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors, the Gemigliptin, Anagliptin, and Teneligliptin are projected to hold a significant share in the market. Geographically, the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into China, India, Japan, ASEAN, South Korea, and the Rest of the World. China and India are anticipated to grow considerably over the forecast period. 

Further, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, Sanwa Kagaku Kenkyusho Co. Ltd. and Takeda Pharmaceutical Co. among others are some of the prominent players functioning in the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market. 

Research Methodology

The market study of the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

• Financial reports of companies involved in the market
• Whitepapers, research-papers, and news blogs
• Company websites and their product catalog

The report is intended for pharmaceutical companies, dipeptidyl peptidase 4 (DPP-4) inhibitors manufacturers, research institutes and universities, other related companies, and government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Asia-Pacific Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Research and Analysis by Drug Type

The Report covers:

• Comprehensive research methodology of the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Asia-Pacific Dipeptidyl peptidase 4 (DPP-4) inhibitors market.
• Insights about market determinants which are stimulating the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market.
• Detailed and extensive market segments with regional distribution of forecast revenues.
• Extensive profiles and recent developments of the market players.